Sep 2026
Abstract B104: Pharmacological RAS inhibition synergizes with CAR T cells for tumor killing
Despite the success of chimeric antigen receptor (CAR) T cell therapy for liquid cancers, it has provided minimal clinical benefit in solid cancers, including pancreatic ductal adenocarcinoma (PDAC). We have previously shown that pharmacological RAS inhibition favorably remodels the PDAC tumor immune microenviron...
Jayne C. McDevitt, Fei-Yan Mo, Connor J. Hennessey et al.
· Cancer Research · 0 citations